{
    "root": "6cb3fa6e-1116-427e-adbe-43bfcd968c11",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dicyclomine Hydrochloride",
    "value": "20250319",
    "ingredients": [
        {
            "name": "DICYCLOMINE HYDROCHLORIDE",
            "code": "CQ903KQA31"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CALCIUM SULFATE, UNSPECIFIED FORM",
            "code": "WAT0DDB505"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Dicyclomine hydrochloride capsules are indicated for the treatment of patients with functional bowel/irritable bowel syndrome.",
    "contraindications": "Dosage must be adjusted to individual patient needs.",
    "warningsAndPrecautions": "Dicyclomine Hydrochloride Capsules, USP, 10 mg\n                  \n                  10 mg white capsules with \"TWi T201\" ink and white body with\"10 mg\" ink, and the capsule contains white to off white powder blend, supplied in bottles of 100 and 1000 capsules. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. \n                  \n                     \n                         NDC 68788-8525-2\t 20 capsules per bottle\n                  \n                  NDC 68788-8525-3\t 30 capsules per bottle\n                  NDC 68788-8525-6\t 60 capsules per bottle\n                  NDC 68788-8525-1\t 100 capsules per bottle",
    "adverseReactions": "Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see Use in Specific Populations (8.4)], nursing mothers [see Use in Specific Populations (8.3)], and in patients with:\n                  \n                     \n                        •unstable cardiovascular status in acute hemorrhage\n                     \n                        •myasthenia gravis [see Warnings and Precautions (5.4)]\n                     \n                     \n                        •glaucoma [see Adverse Reactions (6.3) and Drug Interactions (7.1)]\n                     \n                     \n                        •obstructive uropathy [see Warnings and Precautions (5.8)]\n                     \n                     \n                        •obstructive disease of the gastrointestinal tract [see Warnings and Precautions (5.5)]\n                     \n                     \n                        •severe ulcerative colitis [see Warnings and Precautions (5.7)]\n                     \n                     \n                        •reflux esophagitis"
}